1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The Dwayne Andrews Glioblastoma Research Grant is a grant from Brain Cancer Canada that funds cutting-edge glioblastoma research projects at Canadian institutions. The award of $85,000 has supported research such as gene therapy treatments for aggressive brain cancers and investigations into immunotherapeutic targets.
Recent recipients include researchers at Dalhousie University and other Canadian institutions advancing novel therapeutic approaches to recurrent and treatment-resistant glioblastoma. Eligible applicants are researchers conducting glioblastoma research projects at qualified institutions.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Brain Cancer Canada - Accelerate | Advocate | Transform Patient & Caregiver Resources Patient & Caregiver Resources $85K Grant for Immunotherapeutic Targets for Recurrent Medulloblastoma $85K to Cutting-Edge Recurrent Glioblastoma Research $68,000 Research Grant for Clinical Trial of Anti-Cancer Vaccine Targeting DIPG $85,000 Dwayne Andrews Glioblastoma Research Grant Awarded to Dr. Jeremy Brown at Dalhousie University Advancing a Gene Therapy Treatment for MYCN-Amplified Pediatric Brain Cancer awarded $100K MicroRNAs Research Initiative in Glioblastoma Stem Cells Awarded $85K by Brain Cancer Canada Dr. Shawn Beug at Children’s Hospital of Eastern Ontario, awarded $50,000 for pediatric brain tumour research.
Dr. Cynthia Hawkins and collaborators at The Hospital for Sick Children awarded $100,000 for DIPG/DMG research. Brain Cancer Canada Awards $80,000 towards ground-breaking Adolescent and Young Adult (AYA) Brain Cancer Research. The development of dual function therapies that harness the body's own immune system to kill brain tumour cells in glioblastomas is awarded an $80,000 Brain Cancer Canada research grant.
PO Box 30007 RPO Woodbine Heights cure@braincancercanada. ca Charitable Registration Number PO Box 30007 RPO Woodbine Heights cure@braincancercanada. ca Charitable Registration Number
According to the current listing, eligibility includes: Researchers conducting glioblastoma research projects. Confirm the full requirements in the official notice before applying.
The current listing shows $85,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The Dwayne Andrews Glioblastoma Research Grant is funded by Brain Cancer Canada. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
ARPA-H's HEARING program (ARPA-H-SOL-26-154) — Hearing Enhancement through ARtificially Intelligent NeurotechnoloGy — held its Proposers' Day on June 8, 2026 and set Solution Summary deadlines for June 29 with Full Proposals due August 14. Single prime awardee, multiple Other Transaction Agreements, three integrated technical areas spanning intracortical recording and stimulation devices, wearable dynamic sound modulators, and AI-based auditory read/write algorithms. The first phase runs 18 months; the full effort runs 4.5 years through first-in-human clinical studies. For neurotech teams that have spent a decade in cochlear-implant or visual-prosthesis space, this is the moment the federal government bet on auditory cortex over the cochlea.
Read articleA Nature poll finds three-quarters of American scientists are considering working abroad. ERC applications from U.S. researchers have tripled. France and the EU pledged €500 million to recruit them. Inside the brain drain reshaping global science — and what it means for grant strategy.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read article